Dr. Woyach on 3-Year Follow-Up of Acalabrutinib/Obinutuzumab Combo in CLL

3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLLПодробнее

Combined acalabrutinib treatments for CLLПодробнее

Acalabrutinib, venetoclax and obinutuzumab upfront for CLLПодробнее

Acalabrutinib Shows Promising Results for the Treatment of CLLПодробнее

MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLLПодробнее

Dr. Woyach on the Safety of Acalabrutinib Versus Ibrutinib in CLLПодробнее

Dr. Woyach on the Role of Acalabrutinib in CLLПодробнее

Acalabrutinib-obinutuzumab in CLL: 3-year follow-upПодробнее

ASCEND: 3 year follow-up of acalabrutinib in R/R CLLПодробнее

Dr. Woyach on the Role of Chemoimmunotherapy in CLLПодробнее

5-year update of ELEVATE CLL TNПодробнее

Seizing the day with BTK inhibitors in CLLПодробнее

Christine Ryan, MD, Discusses Phase II Results of Acalabrutinib, Venetoclax, Obinutuzumab in CLLПодробнее

Dr. Woyach on the Results of the ELEVATE-TN TrialПодробнее

6-year follow-up of ELEVATE-TN: sustained safety and efficacy in CLLПодробнее

Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLLПодробнее

Watch Drs.Lamanna & Woyach discuss the latest CLL updates from #SOHO2021: https://bit.ly/3DZVZDSПодробнее

Dr. Woyach on Ibrutinib Resistance in CLLПодробнее

Acalabrutinib Appears Tolerable in Chronic Lymphocytic LeukemiaПодробнее